Nanomaterial-Mediated Radiotherapy–Immunotherapy Combinations: Breaking Immunosuppression and Revolutionizing Cancer Treatment

Abstract

Malignant tumors remain a leading cause of global mortality. Radiotherapy (RT) and immunotherapy are established cornerstone therapies for most solid cancers. Their combination, radio-immunotherapy (IRT), has demonstrated robust synergistic antitumor activity in preclinical models and early-phase clinical trials. However, broader clinical implementation is hindered by intrinsic or acquired radioresistance, systemic toxicities with overlapping organ tropism, and a profoundly immunosuppressive tumor immune microenvironment (TIME). To address these limitations, this review presents a mechanistically integrated framework centered on nanomaterial-enabled strategies: targeted radiosensitization coupled with enhanced immunogenic cell death (ICD); spatiotemporally controlled remodeling of the TIME to counteract immunosuppression; and multifunctional, imaging-guided theranostic platforms for precision IRT delivery and response monitoring. We systematically synthesize recent preclinical advances in nanomaterial-enhanced IRT—including applications across conventional X-ray, proton beam, photothermal, and sonodynamic irradiation—and critically evaluate early-phase clinical data for representative nanotherapeutics (NBTXR3 and AGuIX). Furthermore, we identify and analyze key translational bottlenecks impeding clinical adoption, including scalability, regulatory pathway clarity, and biomarker-driven patient selection. Collectively, this review provides a unified, mechanism-informed foundation to advance rational nanomaterial design and evidence-based clinical translation, thereby strengthening the scientific basis for precision oncology in patients with refractory solid tumors.

Keywords

immune-radiotherapy (IRT) / immunotherapy / nanomaterials / radiotherapy / tumor immune microenvironment (TIME)

References

[1] Y. Wang, Q. Yan, C. Fan, et al., “Overview and Countermeasures of Cancer Burden in China,” Science China Life Sciences 66, no. 11 (2023): 2515–2526.

[2] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer Statistics, 2022,” CA: A Cancer Journal for Clinicians 72, no. 1 (2022): 7–33.

[3] L. Wyld, R. A. Audisio, and G. J. Poston, “The Evolution of Cancer Surgery and Future Perspectives,” Nature Reviews Clinical Oncology 12, no. 2 (2015): 115–124.

[4] M. T. Amjad, A. Chidharla, and A. Kasi, “Cancer Chemotherapy,” in StatPearls (StatPearls Publishing, 2024).

[5] D. Woods and J. J. Turchi, “Chemotherapy Induced DNA Damage Response: Convergence of Drugs and Pathways,” Cancer Biology & Therapy 14, no. 5 (2013): 379–389.

[6] C. Smith and V. Prasad, “Targeted Cancer Therapies,” American Family Physician 103, no. 3 (2021): 155–163.

[7] Y. T. Lee, Y. J. Tan, and C. E. Oon, “Molecular Targeted Therapy: Treating Cancer With Specificity,” European Journal of Pharmacology 834 (2018): 188–196.

[8] S. Kunte, J. Abraham, and A. J. Montero, “Novel HER2-Targeted Therapies for HER2–Positive Metastatic Breast Cancer,” Cancer 126, no. 19 (2020): 4278–4288.

[9] K. Yoneda, N. Imanishi, Y. Ichiki, and F. Tanaka, “Treatment of Non-Small Cell Lung Cancer With EGFR-Mutations,” Journal of UOEH 41, no. 2 (2019): 153–163.

[10] C. L. Vogel, M. A. Johnston, C. Capers, and D. Braccia, “Toremifene for Breast Cancer: A Review of 20 Years of Data,” Clinical Breast Cancer 14, no. 1 (2014): 1–9.

[11] S. Zhang, S. Zhao, and X. Fu, “Intensity Modulated Radiotherapy in Combination With Endocrinotherapy in the Treatment of Middle and Advanced Prostatic Cancer: Treatment of Middle and Advanced Prostatic Cancer,” Pakistan Journal of Medical Sciences 35, no. 5 (2019): 1264–1269.

[12] B. A. Rupnow, A. D. Murtha, R. M. Alarcon, A. J. Giaccia, and S. J. Knox, “Direct Evidence That Apoptosis Enhances Tumor Responses to Fractionated Radiotherapy,” Cancer Research 58, no. 9 (1998): 1779–1784.

[13] D. Eriksson and T. Stigbrand, “Radiation-Induced Cell Death Mechanisms,” Tumor Biology 31, no. 4 (2010): 363–372.

[14] M. M. Gonzales Carazas, J. A. Pinto, and F. L. Casado, “Biological Bases of Cancer Immunotherapy,” Expert Reviews in Molecular Medicine 23 (2021): e3.

[15] C. M. Nutting, J. P. Morden, K. J. Harrington, et al., “Parotid-Sparing Intensity Modulated Versus Conventional Radiotherapy in Head and Neck Cancer (Parsport): a Phase 3 Multicentre Randomised Controlled Trial,” Lancet Oncology 12, no. 2 (2011): 127–136.

[16] K. Numakura, M. Kobayashi, Y. Muto, et al., “The Current Trend of Radiation Therapy for Patients With Localized Prostate Cancer,” Current Oncology 30, no. 9 (2023): 8092–8110.

[17] W. I. Jang, S. Jo, J. E. Moon, et al., “The Current Evidence of Intensity-Modulated Radiotherapy for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis,” Cancers 15, no. 20 (2023): 4919

[18] J. Y. Chang, S. H. Lin, W. Dong, et al., “Stereotactic Ablative Radiotherapy With or Without Immunotherapy for Early-Stage or Isolated Lung Parenchymal Recurrent Node-Negative Non-Small-Cell Lung Cancer: An Open-Label, Randomised, Phase 2,” Lancet 402, no. 10405 (2023): 871–881.

[19] R. Mohan and D. Grosshans, “Proton Therapy – Present and Future,” Advanced Drug Delivery Reviews 109 (2017): 26–44.

[20] K. C. Cuneo and D. J. Herr, “Advances in Radiation Therapy for Primary Liver Cancer,” Surgical Oncology Clinics of North America 32, no. 3 (2023): 415–432.

[21] A. Fozza, F. De Rose, M. C. De Santis, et al., “Technological Advancements and Future Perspectives in Breast Cancer Radiation Therapy,” Expert Review of Anticancer Therapy 23, no. 4 (2023): 407–419.

[22] A. U. Kishan, T. M. Ma, J. M. Lamb, et al., “Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial,” JAMA Oncology 9, no. 3 (2023): 365–373.

[23] K. Koka, A. Verma, B. S. Dwarakanath, et al., “Technological Advancements in External Beam Radiation Therapy (EBRT): An Indispensable Tool for Cancer Treatment,” Cancer Management and Research 14 (2022): 1421–1429.

[24] S. L. Topalian, F. S. Hodi, J. R. Brahmer, et al., “Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer,” New England Journal of Medicine 366, no. 26 (2012): 2443–2454.

[25] S. Novello, D. M. Kowalski, A. Luft, et al., “Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study,” Journal of Clinical Oncology 41, no. 11 (2023): 1999–2006.

[26] L. Paz-Ares, T. E. Ciuleanu, M. Cobo, et al., “First-Line Nivolumab Plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (Checkmate 9LA): An International, Randomised, Open-Label, Phase 3 Trial,” Lancet Oncology 22, no. 2 (2021): 198–211.

[27] F. Acker, M. Reck, D. Martin, et al., “Efficacy and Safety of Immune Checkpoint Inhibition Combined With Concurrent Chemoradiotherapy in Patients With Stage III Unresectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis,” European Journal of Cancer 218 (2025): 115266.

[28] C. Peterson, N. Denlinger, and Y. Yang, “Recent Advances and Challenges in Cancer Immunotherapy,” Cancers 14, no. 16 (2022): 3972.

[29] Z. Zheng, J. Liu, J. Ma, R. Kang, Z. Liu, and J. Yu, “Advances in New Targets for Immunotherapy of Small Cell Lung Cancer,” Thoracic Cancer 15, no. 1 (2024): 3–14.

[30] K. Pan, H. Farrukh, V. C. S. R. Chittepu, H. Xu, C. Pan, and Z. Zhu, “CAR Race to Cancer Immunotherapy: From CAR T, CAR NK to CAR Macrophage Therapy,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 119.

[31] M. Włodarczyk and B. Pyrzynska, “CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy Against Cancer,” Cancers 15, no. 1 (2022): 117.

[32] J. Xie, Z. Zheng, L. Tuo, et al., “Recent Advances in Exosome-Based Immunotherapy Applied to Cancer,” Frontiers in Immunology 14 (2023): 1296857.

[33] D. Bojar and F. Lisacek, “Glycoinformatics in the Artificial Intelligence Era,” Chemical Reviews 122, no. 20 (2022): 15971–15988.

[34] J. Xie, W. Tian, Y. Tang, et al., “Establishment of a Cell Necroptosis Index to Predict Prognosis and Drug Sensitivity for Patients With Triple-Negative Breast Cancer,” Frontiers in Molecular Biosciences 9 (2022): 834593.

[35] F. Huemer, M. Leisch, R. Geisberger, et al., “Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence,” International Journal of Molecular Sciences 21 (2020): 8.

[36] Y. Hu, Z. Zhao, Y. Ma, et al., “Targeting MAO Offers a Novel Immunotherapeutic Strategy for Prostate Cancer by Modulating the “Tumor-Stroma-Immune” Interaction Network,” Biochimica et Biophysica Acta, Reviews on Cancer 1881, no. 1 (2025): 189506.

[37] J. Shan, D. Han, C. Shen, Q. Lei, and Y. Zhang, “Mechanism and Strategies of Immunotherapy Resistance in Colorectal Cancer,” Frontiers in immunology 13 (2022): 1016646.

[38] P. Fang, J. Zhou, Z. Liang, et al., “Immunotherapy Resistance in Esophageal Cancer: Possible Mechanisms and Clinical Implications,” Frontiers in immunology 13 (2022): 975986.

[39] G. M. Whitesides, “The 'Right' Size in Nanobiotechnology,” Nature Biotechnology 21, no. 10 (2003): 1161–1165.

[40] S. Bayda, M. Adeel, T. Tuccinardi, et al., “The History of Nanoscience and Nanotechnology: From Chemical-Physical Applications to Nanomedicine,” Molecules 25 (2019): 1.

[41] D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, “Nanocarriers as an Emerging Platform for Cancer Therapy,” Nature Nanotechnology 2, no. 12 (2007): 751–760.

[42] M. Xu, X. Han, H. Xiong, et al., “Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials,” Molecules 28, no. 13 (2023): 5145.

[43] A. Singh and M. M. Amiji, “Application of Nanotechnology in Medical Diagnosis and Imaging,” Current Opinion in Biotechnology 74 (2022): 241–246.

[44] H. U. Rashid, M. a U. Martines, J. Jorge, et al., “Cyclen-Based Gd3+ Complexes as MRI Contrast Agents: Relaxivity Enhancement and Ligand Design,” Bioorganic & Medicinal Chemistry 24, no. 22 (2016): 5663–5684.

[45] Y. X. Wang, “Superparamagnetic Iron Oxide Based MRI Contrast Agents: Current Status of Clinical Application,” Quantitative Imaging in Medicine and Surgery 1, no. 1 (2011): 35–40.

[46] S. Wen, L. Zhao, Q. Zhao, et al., “A Promising Dual Mode SPECT/CT Imaging Platform Based on99mTc-Labeled Multifunctional Dendrimer-Entrapped Gold Nanoparticles,” Journal of Materials Chemistry B 5, no. 21 (2017): 3810–3815.

[47] K. R. Tringale, J. Pang, and Q. T. Nguyen, “Image-Guided Surgery in Cancer: A Strategy to Reduce Incidence of Positive Surgical Margins,” Wiley Interdisciplinary Reviews: Systems Biology and Medicine 10, no. 3 (2018): e1412.

[48] H. Cheng, C. Chi, W. Shang, et al., “Precise Integrin-Targeting Near-Infrared Imaging-Guided Surgical Method Increases Surgical Qualification of Peritoneal Carcinomatosis From Gastric Cancer in Mice,” Oncotarget 8, no. 4 (2017): 6258–6272.

[49] K. Yogo, M. Misawa, M. Shimizu, et al., “Effect of Gold Nanoparticle Radiosensitization on Plasmid DNA Damage Induced by High-Dose-Rate Brachytherapy,” International Journal of Nanomedicine 16 (2021): 359–370.

[50] F. M. Kievit, Z. R. Stephen, K. Wang, et al., “Nanoparticle Mediated Silencing of DNA Repair Sensitizes Pediatric Brain Tumor Cells to γ-Irradiation,” Molecular Oncology 9, no. 6 (2015): 1071–1080.

[51] J. F. Hainfeld, H. M. Smilowitz, M. J. O‘Connor, F. A. Dilmanian, and D. N. Slatkin, “Gold Nanoparticle Imaging and Radiotherapy of Brain Tumors in Mice,” Nanomedicine 8, no. 10 (2013): 1601–1609.

[52] D. A. Lavan, T. Mcguire, and R. Langer, “Small-Scale Systems for In Vivo Drug Delivery,” Nature Biotechnology 21, no. 10 (2003): 1184–1191.

[53] M. Ferrari, “Cancer Nanotechnology: Opportunities and Challenges,” Nature Reviews Cancer 5, no. 3 (2005): 161–171.

[54] O. C. Farokhzad, J. M. Karp, and R. Langer, “Nanoparticle–Aptamer Bioconjugates for Cancer Targeting,” Expert Opinion on Drug Delivery 3, no. 3 (2006): 311–324.

[55] L. Zhang, F. Gu, J. Chan, A. Wang, R. Langer, and O. Farokhzad, “Nanoparticles in Medicine: Therapeutic Applications and Developments,” Clinical Pharmacology & Therapeutics 83, no. 5 (2008): 761–769.

[56] T. Yong, X. Zhang, N. Bie, et al., “Tumor Exosome-Based Nanoparticles Are Efficient Drug Carriers for Chemotherapy,” Nature Communications 10, no. 1 (2019): 3838.

[57] D. J. Irvine and E. L. Dane, “Enhancing Cancer Immunotherapy With Nanomedicine,” Nature Reviews Immunology 20, no. 5 (2020): 321–334.

[58] S. Guo, M. Vieweger, K. Zhang, et al., “Ultra-Thermostable RNA Nanoparticles for Solubilizing and High-Yield Loading of Paclitaxel for Breast Cancer Therapy,” Nature Communications 11, no. 1 (2020): 972.

[59] J. Q. Liu, C. Zhang, X. Zhang, et al., “Intratumoral Delivery of IL-12 and IL-27 mRNA Using Lipid Nanoparticles for Cancer Immunotherapy,” Journal of Controlled Release 345 (2022): 306–313.

[60] Y. Zeng, S. Li, S. Zhang, L. Wang, H. Yuan, and F. Hu, “Cell Membrane Coated-Nanoparticles for Cancer Immunotherapy,” Acta Pharmaceutica Sinica B 12, no. 8 (2022): 3233–3254.

[61] S. Karve, M. E. Werner, R. Sukumar, et al., “Revival of the Abandoned Therapeutic Wortmannin by Nanoparticle Drug Delivery,” Proceedings of the National Academy of Sciences 109, no. 21 (2012): 8230–8235.

[62] M. C. Mcgee, J. B. Hamner, R. F. Williams, et al., “Improved Intratumoral Oxygenation Through Vascular Normalization Increases Glioma Sensitivity to Ionizing Radiation,” International Journal of Radiation Oncology Biology Physics 76, no. 5 (2010): 1537–1545.

[63] M. I. Koukourakis, S. M. Bentzen, A. Giatromanolaki, et al., “Endogenous Markers of Two Separate Hypoxia Response Pathways (Hypoxia Inducible Factor 2 Alpha and Carbonic Anhydrase 9) Are Associated With Radiotherapy Failure in Head and Neck Cancer Patients Recruited in the CHART Randomized Trial,” Journal of Clinical Oncology 24, no. 5 (2006): 727–735.

[64] H. Xiong, D. Zhou, Y. Qi, et al., “Doxorubicin-Loaded Carborane-Conjugated Polymeric Nanoparticles as Delivery System for Combination Cancer Therapy,” Biomacromolecules 16, no. 12 (2015): 3980–3988.

[65] E. C. Ko and S. C. Formenti, “Radiation Therapy to Enhance Tumor Immunotherapy: A Novel Application for an Established Modality,” International Journal of Radiation Biology 95, no. 7 (2019): 936–939.

[66] J. Fucikova, O. Kepp, L. Kasikova, et al., “Detection of Immunogenic Cell Death and Its Relevance for Cancer Therapy,” Cell Death & Disease 11, no. 11 (2020): 1013.

[67] Q. Chen, J. Chen, Z. Yang, et al., “Nanoparticle-Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy,” Advanced Materials 31, no. 10 (2019): e1802228.

[68] K. Lu, C. He, N. Guo, et al., “Low-Dose X-Ray Radiotherapy–Radiodynamic Therapy via Nanoscale Metal–Organic Frameworks Enhances Checkpoint Blockade Immunotherapy,” Nature Biomedical Engineering 2, no. 8 (2018): 600–610.

[69] Z. Yang, Y. Zhu, Z. Dong, et al., “Tumor-Killing Nanoreactors Fueled by Tumor Debris Can Enhance Radiofrequency Ablation Therapy and Boost Antitumor Immune Responses,” Nature Communications 12, no. 1 (2021): 4299.

[70] Y. Zhang, Z. Feng, J. Liu, et al., “Polarization of Tumor-Associated Macrophages by TLR7/8 Conjugated Radiosensitive Peptide Hydrogel for Overcoming Tumor Radioresistance,” Bioactive Materials 16 (2022): 359–371.

[71] S. Demaria, C. Guha, J. Schoenfeld, et al., “Radiation Dose and Fraction in Immunotherapy: One-Size Regimen Does Not Fit All Settings, so How Does One Choose?,” Journal for Immunotherapy of Cancer 9 (2021): e002038.

[72] R. B. Patel, M. Ye, P. M. Carlson, et al., “Development of an in Situ Cancer Vaccine via Combinational Radiation and Bacterial-Membrane-Coated Nanoparticles,” Advanced Materials 31, no. 43 (2019): e1902626.

[73] C. Vanpouille-Box, A. Alard, M. J. Aryankalayil, et al., “DNA Exonuclease Trex1 Regulates Radiotherapy-Induced Tumour Immunogenicity,” Nature Communications 8 (2017): 15618.

[74] Z. S. Morris, E. I. Guy, D. M. Francis, et al., “In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments,” Cancer Research 76, no. 13 (2016): 3929–3941.

[75] S. S. Park, H. Dong, X. Liu, et al., “PD-1 Restrains Radiotherapy-Induced Abscopal Effect,” Cancer Immunology Research 3, no. 6 (2015): 610–619.

[76] Y. Wu, M. Yi, M. Niu, B. Zhou, Q. Mei, and K. Wu, “Beyond Success: Unveiling the Hidden Potential of Radiotherapy and Immunotherapy in Solid Tumors,” Cancer Communications 44, no. 7 (2024): 739–760.

[77] Y. Hou, K. Yang, L. Wang, et al., “Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites,” Clinical Cancer Research 30, no. 9 (2024): 1945–1958.

[78] J. Tang, B. Malachowska, X. Wu, and C. Guha, “Repurposing Radiation Therapy for Immuno-Oncology,” Clinical Oncology 33, no. 11 (2021): 683–693.

[79] W. L. Hwang, L. R. G. Pike, T. J. Royce, B. A. Mahal, and J. S. Loeffler, “Safety of Combining Radiotherapy With Immune-Checkpoint Inhibition,” Nature Reviews Clinical Oncology 15, no. 8 (2018): 477–494.

[80] E. Deutsch, C. Chargari, L. Galluzzi, and G. Kroemer, “Optimising Efficacy and Reducing Toxicity of Anticancer Radioimmunotherapy,” Lancet Oncology 20, no. 8 (2019): e452–e463.

[81] A. Ludin and L. I. Zon, “The Dark Side of PD-1 Receptor Inhibition,” Nature 552, no. 7683 (2017): 41–42.

[82] E. C. Ko, D. Raben, and S. C. Formenti, “The Integration of Radiotherapy With Immunotherapy for the Treatment of Non–Small Cell Lung Cancer,” Clinical Cancer Research 24, no. 23 (2018): 5792–5806.

[83] M. B. Barton, S. Jacob, J. Shafiq, et al., “Estimating the Demand for Radiotherapy From the Evidence: A Review of Changes From 2003 to 2012,” Radiotherapy and Oncology 112, no. 1 (2014): 140–144.

[84] S. Rana and C. Cheng, “Radiobiological Impact of Planning Techniques for Prostate Cancer in Terms of Tumor Control Probability and Normal Tissue Complication Probability,” Annals of Medical and Health Sciences Research 4, no. 2 (2014): 167–172.

[85] E. A. Salvanou, D. Stellas, C. Tsoukalas, et al., “A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled With the Alpha-Emitter Actinium-225,” Pharmaceutics 12 (2020): 188.

[86] Y. Chen, J. Yang, S. Fu, et al., “Gold Nanoparticles as Radiosensitizers in Cancer Radiotherapy,” International Journal of Nanomedicine 15 (2020): 9407–9430.

[87] F. Shiridokht, P. Kehtari, M. Eskandani, A. Farajollahi, and S. Vandghanooni, “Advancing Cancer Radiotherapy: Harnessing Radiosensitizers and Nanotechnology for Enhanced Tumor Control,” International Journal of Pharmaceutics: X 10 (2025): 100419.

[88] N. Jackson, D. Cecchi, W. Beckham, and D. B. Chithrani, “Application of High-Z Nanoparticles to Enhance Current Radiotherapy Treatment,” Molecules 29 (2024): 2438.

[89] G. Lei, Y. Zhang, P. Koppula, et al., “The Role of Ferroptosis in Ionizing Radiation-Induced Cell Death and Tumor Suppression,” Cell Research 30, no. 2 (2020): 146–162.

[90] L. F. Ye, K. R. Chaudhary, F. Zandkarimi, et al., “Radiation-Induced Lipid Peroxidation Triggers Ferroptosis and Synergizes With Ferroptosis Inducers,” ACS Chemical Biology 15, no. 2 (2020): 469–484.

[91] G. Lei, C. Mao, Y. Yan, L. Zhuang, and B. Gan, “Ferroptosis, Radiotherapy, and Combination Therapeutic Strategies,” Protein & Cell 12, no. 11 (2021): 836–857.

[92] J. Su, C. Bian, Z. Zheng, et al., “Cooperation Effects of Radiation and Ferroptosis on Tumor Suppression and Radiation Injury,” Frontiers in Cell and Developmental Biology 10 (2022): 951116.

[93] X. Lang, M. D. Green, W. Wang, et al., “Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11,” Cancer Discovery 9, no. 12 (2019): 1673–1685.

[94] C. Bae, R. Hernández Millares, S. Ryu, et al., “Synergistic Effect of Ferroptosis-Inducing Nanoparticles and X-Ray Irradiation Combination Therapy,” Small 20, no. 19 (2024): e2310873.

[95] J. F. Hainfeld, D. N. Slatkin, T. M. Focella, and H. M. Smilowitz, “Gold Nanoparticles: A New X-Ray Contrast Agent,” British Journal of Radiology 79, no. 939 (2006): 248–253.

[96] T. Sato, Y. Kakei, T. Hasegawa, et al., “Gold Nanoparticles Enhance the Tumor Growth-Suppressing Effects of Cetuximab and Radiotherapy in Head and Neck Cancer In Vitro and In Vivo,” Cancers 15, no. 23 (2023): 5697.

[97] M. A. Kouri, E. Spyratou, M. E. Kalkou, et al., “Nanoparticle-Mediated Radiotherapy: Unraveling Dose Enhancement and Apoptotic Responses in Cancer and Normal Cell Lines,” Biomolecules 13 (2023): 1720.

[98] Y. Gholami, X. Zhu, R. Fulton, S. Meikle, G. El-Fakhri, and Z. Kuncic, “Stochastic Simulation of Radium-223 Dichloride Therapy at the Sub-Cellular Level,” Physics in Medicine and Biology 60, no. 15 (2015): 6087–6096.

[99] H. Jadvar, “Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment,” American Journal of Roentgenology 209, no. 2 (2017): 277–288.

[100] V. M. Petriev, V. K. Tischenko, A. A. Mikhailovskaya, et al., “Nuclear Nanomedicine Using Si Nanoparticles as Safe and Effective Carriers of 188Re Radionuclide for Cancer Therapy,” Scientific Reports 9, no. 1 (2019): 2017.

[101] E. C. Pratt, T. M. Shaffer, Q. Zhang, C. M. Drain, and J. Grimm, “Nanoparticles as Multimodal Photon Transducers of Ionizing Radiation,” Nature Nanotechnology 13, no. 5 (2018): 418–426.

[102] Y. H. Gholami, R. Maschmeyer, and Z. Kuncic, “Radio-Enhancement Effects by Radiolabeled Nanoparticles,” Scientific Reports 9, no. 1 (2019): 14346.

[103] M. W. Huang, S. M. Liu, L. Zheng, et al., “A Digital Model Individual Template and CT-Guided 125I Seed Implants for Malignant Tumors of the Head and Neck,” Journal of Radiation Research 53, no. 6 (2012): 973–977.

[104] X. Hu, H. Qiu, L. Zhang, et al., “Recurrent Gliomas: Comparison of Computed Tomography (CT)-Guided125I Seed Implantation Therapy and Traditional Radiochemotherapy,” Cancer Biology & Therapy 13, no. 10 (2012): 840–847.

[105] J. Chin, R. B. Rumble, and D. A. Loblaw, “Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update Summary,” Journal of Oncology Practice 13, no. 6 (2017): 392–394.

[106] Z. Ji, Y. Jiang, S. Tian, et al., “The Effectiveness and Prognostic Factors of CT-Guided Radioactive I-125 Seed Implantation for the Treatment of Recurrent Head and Neck Cancer After External Beam Radiation Therapy,” International Journal of Radiation Oncology Biology Physics 103, no. 3 (2019): 638–645.

[107] Y. Chen, Y. Jiang, Z. Ji, et al., “Efficacy and Safety of CT-Guided 125I Seed Implantation as a Salvage Treatment for Locally Recurrent Head and Neck Soft Tissue Sarcoma After Surgery and External Beam Radiotherapy: A 12-Year Study at a Single Institution,” Brachytherapy 19, no. 1 (2020): 81–89.

[108] R. Wang, H. Liu, B. Antal, H. T. Wolterbeek, and A. G. Denkova, “Ultrasmall Gold Nanoparticles Radiolabeled With Iodine-125 as Potential New Radiopharmaceutical,” ACS Applied Bio Materials 7, no. 2 (2024): 1240–1249.

[109] C. C. Woo, A. P. Kumar, G. Sethi, and K. H. B. Tan, “Thymoquinone: Potential Cure for Inflammatory Disorders and Cancer,” Biochemical Pharmacology 83, no. 4 (2012): 443–451.

[110] B. Sperker, U. Werner, T. E. Mürdter, et al., “Expression and Function of β-Glucuronidase in Pancreatic Cancer: Potential Role in Drug Targeting,” Naunyn-Schmiedeberg's Archives of Pharmacology 362, no. 2 (2000): 110–115.

[111] Y. C. Su, T. C. Cheng, Y. L. Leu, et al., “PET Imaging of β-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy,” Molecular Cancer Therapeutics 13, no. 12 (2014): 2852–2863.

[112] İ. İnce, Z. B. Müftüler, E. İ. Medine, et al., “Thymoquinone Glucuronide Conjugated Magnetic Nanoparticle for Bimodal Imaging and Treatment of Cancer as a Novel Theranostic Platform,” Current Radiopharmaceuticals 14, no. 1 (2021): 23–36.

[113] J. Choi, W. Beaino, R. J. Fecek, et al., “Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma,” Journal of Nuclear Medicine 59, no. 12 (2018): 1843–1849.

[114] W. Mier, C. Kratochwil, J. C. Hassel, et al., “Radiopharmaceutical Therapy of Patients With Metastasized Melanoma With the Melanin-Binding Benzamide131I-BA52,” Journal of Nuclear Medicine 55, no. 1 (2014): 9–14.

[115] K. Ma, C. Mendoza, M. Hanson, U. Werner-Zwanziger, J. Zwanziger, and U. Wiesner, “Control of Ultrasmall Sub-10 nm Ligand-Functionalized Fluorescent Core–Shell Silica Nanoparticle Growth in Water,” Chemistry of Materials 27, no. 11 (2015): 4119–4133.

[116] K. P. Barteau, K. Ma, F. F. E. Kohle, et al., “Quantitative Measure of the Size Dispersity in Ultrasmall Fluorescent Organic–Inorganic Hybrid Core–Shell Silica Nanoparticles by Small-Angle X-Ray Scattering,” Chemistry of Materials 31, no. 3 (2019): 643–657.

[117] X. Zhang, F. Chen, M. Z. Turker, et al., “Targeted Melanoma Radiotherapy Using Ultrasmall 177Lu-Labeled α-Melanocyte Stimulating Hormone-Functionalized Core-Shell Silica Nanoparticles,” Biomaterials 241 (2020): 119858.

[118] H. Lin, S. Gao, C. Dai, Y. Chen, and J. Shi, “A Two-Dimensional Biodegradable Niobium Carbide (MXene) for Photothermal Tumor Eradication in NIR-I and NIR-II Biowindows,” Journal of the American Chemical Society 139, no. 45 (2017): 16235–16247.

[119] H. S. Jung, P. Verwilst, A. Sharma, J. Shin, J. L. Sessler, and J. S. Kim, “Organic Molecule-Based Photothermal Agents: An Expanding Photothermal Therapy Universe,” Chemical Society Reviews 47, no. 7 (2018): 2280–2297.

[120] D. De Melo-Diogo, C. Pais-Silva, D. R. Dias, et al., “Strategies to Improve Cancer Photothermal Therapy Mediated by Nanomaterials[J],” Advanced Healthcare Materials 6 (2017): 10.

[121] H. S. Han and K. Y. Choi, “Advances in Nanomaterial-Mediated Photothermal Cancer Therapies: Toward Clinical Applications,” Biomedicines 9 (2021): 305.

[122] A. R. Rastinehad, H. Anastos, E. Wajswol, et al., “Gold Nanoshell-Localized Photothermal Ablation of Prostate Tumors in a Clinical Pilot Device Study,” Proceedings of the National Academy of Sciences 116, no. 37 (2019): 18590–18596.

[123] M. Simón, K. Norregaard, J. T. Jørgensen, et al., “Fractionated Photothermal Therapy in a Murine Tumor Model: Comparison With Single Dose,” International Journal of Nanomedicine 14 (2019): 5369–5379.

[124] M. Simón, J. T. Jørgensen, K. Norregaard, and A. Kjaer, “(18)F-FDG Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging for Response Evaluation of Nanoparticle-Mediated Photothermal Therapy,” Scientific Reports 10, no. 1 (2020): 7595.

[125] M. Simón, J. T. Jørgensen, H. A. Khare, C. Christensen, C. H. Nielsen, and A. Kjaer, “Combination of [177Lu] Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model,” Pharmaceutics 14 (2022): 1284.

[126] Z. Zhang, Q. Wang, Q. Liu, et al., “Dual-Locking Nnanoparticles Disrupt the PD-1/PD-L1 Pathway for Efficient Cancer Immunotherapy,” Advanced Materials 31, no. 51 (2019): e1905751.

[127] C. Zheng, Q. Wang, Y. Wang, et al., “In Situ Modification of the Tumor Cell Surface With Immunomodulating Nanoparticles for Effective Suppression of Tumor Growth in Mice,” Advanced Materials 31, no. 32 (2019): e1902542.

[128] Z. Kang, C. Wang, Z. Zhang, et al., “Spatial Distribution Control of Antimicrobial Peptides Through a Novel Polymeric Carrier for Safe and Efficient Cancer Treatment,” Advanced Materials 34, no. 23 (2022): e2201945.

[129] X. Wang, J. Wilhelm, W. Li, et al., “Polycarbonate-Based Ultra-pH Sensitive Nanoparticles Improve Therapeutic Window,” Nature Communications 11, no. 1 (2020): 5828.

[130] J. Yan, G. Wang, L. Xie, et al., “Engineering Radiosensitizer-Based Metal-Phenolic Networks Potentiate STING Pathway Activation for Advanced Radiotherapy,” Advanced Materials 34, no. 10 (2022): e2105783.

[131] X. Sun, Y. Zhang, J. Li, et al., “Amplifying STING Activation by Cyclic Dinucleotide–Manganese Particles for Local and Systemic Cancer Metalloimmunotherapy,” Nature Nanotechnology 16, no. 11 (2021): 1260–1270.

[132] Y. Lee, M. Jeong, J. Park, H. Jung, and H. Lee, “Immunogenicity of Lipid Nanoparticles and Its Impact on the Efficacy of mRNA Vaccines and Therapeutics,” Experimental & Molecular Medicine 55, no. 10 (2023): 2085–2096.

[133] B. Li, A. Y. Jiang, I. Raji, et al., “Enhancing the Immunogenicity of Lipid-Nanoparticle Mrna Vaccines by Adjuvanting the Ionizable Lipid and the mRNA,” Nature Biomedical Engineering no. 9 (2023): 167–184.

[134] M. Binnewies, E. W. Roberts, K. Kersten, et al., “Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy,” Nature Medicine 24, no. 5 (2018): 541–550.

[135] D. Bruni, H. K. Angell, and J. Galon, “The Immune Contexture and Immunoscore in Cancer Prognosis and Therapeutic Efficacy,” Nature Reviews Cancer 20, no. 11 (2020): 662–680.

[136] D. S. Chen and I. Mellman, “Elements of Cancer Immunity and the Cancer–Immune Set Point,” Nature 541, no. 7637 (2017): 321–330.

[137] D. I. Viswanath, H. C. Liu, D. P. Huston, C. Y. X. Chua, and A. Grattoni, “Emerging Biomaterial-Based Strategies for Personalized Therapeutic in Situ Cancer Vaccines,” Biomaterials 280 (2022): 121297.

[138] J. Liu, S. S. Liew, J. Wang, et al., “Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines,” Advanced Materials 34, no. 1 (2022): e2103790.

[139] S. H. Van Der Burg, R. Arens, F. Ossendorp, T. van Hall, and C. J. M. Melief, “Vaccines for Established Cancer: Overcoming the Challenges Posed by Immune Evasion,” Nature Reviews Cancer 16, no. 4 (2016): 219–233.

[140] L. Chen, H. Qin, R. Zhao, et al., “Bacterial Cytoplasmic Membranes Synergistically Enhance the Antitumor Activity of Autologous Cancer Vaccines,” Science Translational Medicine 13, no. 601 (2021).

[141] D. Shae, J. J. Baljon, M. Wehbe, K. W. Becker, T. L. Sheehy, and J. T. Wilson, “At the Bench: Engineering the Next Generation of Cancer Vaccines,” Journal of Leukocyte Biology 108, no. 4 (2020): 1435–1453.

[142] H. C. Chang, Z. Z. Zou, Q. H. Wang, et al., “Targeting and Specific Activation of Antigen-Presenting Cells by Endogenous Antigen-Loaded Nanoparticles Elicits Tumor-Specific Immunity,” Advanced Science 7, no. 1 (2020): 1900069.

[143] K. R. Trabbic, K. A. Kleski, and J. J. Barchi, Jr., “Stable Gold-Nanoparticle-Based Vaccine for the Targeted Delivery of Tumor-Associated Glycopeptide Antigens,” ACS Bio & Med Chem Au 1, no. 1 (2021): 31–43.

[144] Q. Shang, Y. Dong, Y. Su, F. Leslie, M. Sun, and F. Wang, “Local Scaffold-Assisted Delivery of Immunotherapeutic Agents for Improved Cancer Immunotherapy,” Advanced Drug Delivery Reviews 185 (2022): 114308.

[145] A. Z. Obradovic, M. C. Dallos, M. L. Zahurak, et al., “T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer,” Clinical Cancer Research 26, no. 13 (2020): 3182–3192.

[146] C. L. Lorentzen, J. B. Haanen, Ö. Met, and I. M. Svane, “Clinical Advances and Ongoing Trials of mRNA Vaccines for Cancer Treatment,” Lancet Oncology 23, no. 10 (2022): e450–e458.

[147] S. Yan, Z. Luo, Z. Li, et al., “Improving Cancer Immunotherapy Outcomes Using Biomaterials,” Angewandte Chemie International Edition 59, no. 40 (2020): 17332–17343.

[148] J. Xu, J. Lv, Q. Zhuang, et al., “A General Strategy Towards Personalized Nanovaccines Based on Fluoropolymers for Post-Surgical Cancer Immunotherapy,” Nature Nanotechnology 15, no. 12 (2020): 1043–1052.

[149] C. Liu, X. Liu, X. Xiang, et al., “A Nanovaccine for Antigen Self-Presentation and Immunosuppression Reversal as a Personalized Cancer Immunotherapy Strategy,” Nature Nanotechnology 17, no. 5 (2022): 531–540.

[150] L. A. Dykman and N. G. Khlebtsov, “Immunological Properties of Gold Nanoparticles,” Chemical Science 8, no. 3 (2017): 1719–1735.

[151] H. G. Kelly, S. J. Kent, and A. K. Wheatley, “Immunological Basis for Enhanced Immunity of Nanoparticle Vaccines,” Expert Review of Vaccines 18, no. 3 (2019): 269–280.

[152] C. Xu, H. Hong, Y. Lee, et al., “Efficient Lymph Node-Targeted Delivery of Personalized Cancer Vaccines With Reactive Oxygen Species-Inducing Reduced Graphene Oxide Nanosheets,” ACS Nano 14, no. 10 (2020): 13268–13278.

[153] Y. Kim, S. Kang, H. Shin, et al., “Sequential and Timely Combination of a Cancer Nanovaccine With Immune Checkpoint Blockade Effectively Inhibits Tumor Growth and Relapse,” Angewandte Chemie International Edition 59, no. 34 (2020): 14628–14638.

[154] G. Liu, M. Zhu, X. Zhao, and G. Nie, “Nanotechnology-Empowered Vaccine Delivery for Enhancing CD8+ T Cells-Mediated Cellular Immunity,” Advanced Drug Delivery Reviews 176 (2021): 113889.

[155] J. Zhao, Y. Xu, S. Ma, et al., “A Minimalist Binary Vaccine Carrier for Personalized Postoperative Cancer Vaccine Therapy,” Advanced Materials 34, no. 10 (2022): e2109254.

[156] C. Wang, R. Zhang, X. Wei, et al., “Metalloimmunology: The Metal Ion-Controlled Immunity,” Advances in Immunology 145 (2020): 187–241.

[157] M. I. Hood and E. P. Skaar, “Nutritional Immunity: Transition Metals at the Pathogen–Host Interface,” Nature Reviews Microbiology 10, no. 8 (2012): 525–537.

[158] K. Zhang, C. Qi, and K. Cai, “Manganese-Based Tumor Immunotherapy,” Advanced Materials 35, no. 19 (2023): e2205409.

[159] B. Pulendran, P. S. Arunachalam, and D. T. O'Hagan, “Emerging Concepts in the Science of Vaccine Adjuvants,” Nature Reviews Drug Discovery 20, no. 6 (2021): 454–475.

[160] J. Li, H. Ren, and Y. Zhang, “Metal-Based Nano-Vaccines for Cancer Immunotherapy,” Coordination Chemistry Reviews 455 (2022): 214345.

[161] Y. Takagi, A. Okada, K. Sando, M. Wasa, H. Yoshida, and N. Hirabuki, “Evaluation of Indexes of In Vivo Manganese Status and the Optimal Intravenous Dose for Adult Patients Undergoing Home Parenteral Nutrition,” American Journal of Clinical Nutrition 75, no. 1 (2002): 112–118.

[162] R. Rangel-López, M. Franco-Molina, C. Rodríguez-Padilla, et al., “Gold Nanoparticles Synthesized With Triple-Negative Breast Cancer Cell Lysate Enhance Antitumoral Immunity: A Novel Synthesis Method,” Pharmaceuticals (Basel) 18, no. 3 (2025): 30.

[163] B. Ding, P. Zheng, F. Jiang, et al., “Mnoxnanospikes as Nanoadjuvants and Immunogenic Cell Death Drugs With Enhanced Antitumor Immunity and Antimetastatic Effect,” Angewandte Chemie International Edition 59, no. 38 (2020): 16381–16384.

[164] J. Duan, S. Zhao, Y. Duan, et al., “Mno(x) Nanoenzyme Armed CAR-NK Cells Enhance Solid Tumor Immunotherapy by Alleviating the Immunosuppressive Microenvironment,” Advanced Healthcare Materials 13, no. 11 (2024): e2303963.

[165] L. Peng, A. Zhao, R. Li, et al., “Self-Propelled In Situ Polymerized Nanoparticles Activating the STING Pathway for Enhanced Bladder Cancer Immunotherapy,” Advanced Science 12, no. 25 (2025): e2502750.

[166] Y. S. Hong, D. Y. Kim, S. B. Lim, et al., “Preoperative Chemoradiation With Irinotecan and Capecitabine in Patients With Locally Advanced Resectable Rectal Cancer: Long-Term Results of a Phase II Study,” International Journal of Radiation Oncology Biology Physics 79, no. 4 (2011): 1171–1178.

[167] S. Gollins, A. Sun Myint, B. Haylock, et al., “Preoperative Chemoradiotherapy Using Concurrent Capecitabine and Irinotecan in Magnetic Resonance Imaging–Defined Locally Advanced Rectal Cancer: Impact on Long-Term Clinical Outcomes,” Journal of Clinical Oncology 29, no. 8 (2011): 1042–1049.

[168] S. J. Wong, K. Winter, N. J. Meropol, et al., “Radiation Therapy Oncology Group 0247: A Randomized Phase II Study of Neoadjuvant Capecitabine and Irinotecan or Capecitabine and Oxaliplatin With Concurrent Radiotherapy for Patients With Locally Advanced Rectal Cancer,” International Journal of Radiation Oncology Biology Physics 82, no. 4 (2012): 1367–1375.

[169] S. J. Wong, J. Moughan, N. J. Meropol, et al., “Efficacy Endpoints of Radiation Therapy Group Protocol 0247: A Randomized, Phase 2 Study of Neoadjuvant Radiation Therapy Plus Concurrent Capecitabine and Irinotecan or Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer,” International Journal of Radiation Oncology Biology Physics 91, no. 1 (2015): 116–123.

[170] L. Wang, T. Zhang, Y. Zheng, et al., “Combination of Irinotecan Silicasome Nanoparticles With Radiation Therapy Sensitizes Immunotherapy by Modulating the Activation of the cGAS/STING Pathway for Colorectal Cancer,” Materials Today Bio 23 (2023): 100809.

[171] Y. Liu, J. Du, M. Yan, et al., “Biomimetic Enzyme Nanocomplexes and Their Use as Antidotes and Preventive Measures for Alcohol Intoxication,” Nature Nanotechnology 8, no. 3 (2013): 187–192.

[172] Z. Zhang, Y. Gu, Q. Liu, et al., “Spatial Confined Synergistic Enzymes With Enhanced Uricolytic Performance and Reduced Toxicity for Effective Gout Treatment,” Small 14, no. 33 (2018): e1801865.

[173] Z. Zhang, Z. Pan, Q. Li, Q. Huang, L. Shi, and Y. Liu, “Rational Design of ICD-Inducing Nanoparticles for Cancer Immunotherapy,” Science Advances 10, no. 6 (2024): eadk0716.

[174] C. Li, L. Wang, K. Zhang, et al., “Overcoming Neutrophil-Induced Immunosuppression in Postoperative Cancer Therapy: Combined Sialic Acid-Modified Liposomes With Scaffold-Based Vaccines,” Asian Journal of Pharmaceutical Sciences 19, no. 2 (2024): 100906.

[175] J. Forster, 3rd, A. Fish, M. Malhotra, et al., “Engineered Immunoagonist Non-Coding RNA (IncRNA) Activates Dual TLR Pathways for Cancer Immunotherapy,” Advanced Healthcare Materials 15, no. 2 (2025): e03771.

[176] Y. Pan, R. Chen, X. Lv, et al., “Targeted Delivery of IFN-α-anti-GPC3 Fusion Protein via mRNA-LNP Platform Elicits Potent Anti-Tumor Immunity in Hepatocellular Carcinoma,” Drug Delivery and Translational Research 16. no.2 (2025): 563–578.

[177] H. Pan, M. Zheng, A. Ma, et al., “Cell/Bacteria-Based Bioactive Materials for Cancer Immune Modulation and Precision Therapy,” Advanced Materials 33, no. 50 (2021): e2100241.

[178] U. Erdbrügger, C. J. Blijdorp, I. V. Bijnsdorp, et al., “Urinary Extracellular Vesicles: A Position Paper by the Urine Task Force of the International Society for Extracellular Vesicles,” Journal of Extracellular Vesicles 10, no. 7 (2021): e12093.

[179] C. Gao, Q. Wang, J. Li, et al., “In Vivo Hitchhiking of Immune Cells by Intracellular Self-Assembly of Bacteria-Mimetic Nanomedicine for Targeted Therapy of Melanoma,” Science Advances 8, no. 19 (2022): eabn1805.

[180] C. Qiao, X. Wang, G. Liu, et al., “Erythrocyte Membrane Camouflaged Metal–Organic Framework Nanodrugs for Remodeled Tumor Microenvironment and Enhanced Tumor Chemotherapy,” Advanced Functional Materials 32, no. 6 (2022): 2107791.

[181] L.-L. Bu, L. Rao, G.-T. Yu, et al., “Cancer Stem Cell-Platelet Hybrid Membrane-Coated Magnetic Nanoparticles for Enhanced Photothermal Therapy of Head and Neck Squamous Cell Carcinoma,” Advanced Functional Materials 29, no. 10 (2019): 1807733.

[182] F. Oroojalian, M. Beygi, B. Baradaran, A. Mokhtarzadeh, and M. A. Shahbazi, “Immune Cell Membrane-Coated Biomimetic Nanoparticles for Targeted Cancer Therapy,” Small 17, no. 12 (2021): e2006484.

[183] Z. Guo, I. Noh, A. T. Zhu, et al., “Cancer Cell Membrane Nanodiscs for Antitumor Vaccination,” Nano Letters 23, no. 17 (2023): 7941–7949.

[184] A. N. Barclay and T. K. Van Den Berg, “The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target,” Annual Review of Immunology 32 (2014): 25–50.

[185] V. V. Glinsky, G. V. Glinsky, O. V. Glinskii, et al., “Intravascular Metastatic Cancer Cell Homotypic Aggregation at the Sites of Primary Attachment to the Endothelium,” Cancer Research 63, no. 13 (2003): 3805–3811.

[186] R. H. Fang, W. Gao, and L. Zhang, “Targeting Drugs to Tumours Using Cell Membrane-Coated Nanoparticles,” Nature Reviews Clinical Oncology 20, no. 1 (2023): 33–48.

[187] D. Wang, H. Dong, M. Li, et al., “Erythrocyte–Cancer Hybrid Membrane Camouflaged Hollow Copper Sulfide Nanoparticles for Prolonged Circulation Life and Homotypic-Targeting Photothermal/Chemotherapy of Melanoma,” ACS Nano 12, no. 6 (2018): 5241–5252.

[188] R. Yang, J. Xu, L. Xu, et al., “Cancer Cell Membrane-Coated Adjuvant Nanoparticles With Mannose Modification for Effective Anticancer Vaccination,” ACS Nano 12, no. 6 (2018): 5121–5129.

[189] M. L. Lee, L. Wang, J. C. H. Chen, et al., “Multifunctional Hybrid Membrane-Coated Nanomotors for Magnetically Guided, Cascade-Activated Chemoimmunotherapy for Triple-Negative Breast Cancer,” ACS Applied Materials & Interfaces 17, no.31 (2025): 51643–51658.

[190] H. Chen, X. Cai, J. Zhang, et al., “Activated Dendritic Cell Membrane-Engineered Nanoformulation of Metallo-Immunomodulators as Lysosome-Targeted Adjuvants for Synergistic Cancer Immunotherapy,” Advanced Healthcare Materials (2025): e02409.

[191] S. Sun, Y. He, J. Xu, et al., “Enhancing Cell Pyroptosis With Biomimetic Nanoparticles for Melanoma Chemo-Immunotherapy,” Journal of Controlled Release 367 (2024): 470–485.

[192] P. T. Dean and S. B. Hooks, “Pleiotropic Effects of the COX-2/PGE2 Axis in the Glioblastoma Tumor Microenvironment,” Frontiers in Oncology 12 (2022): 1116014.

[193] M. Yi, D. Jiao, H. Xu, et al., “Biomarkers for Predicting Efficacy of PD-1/PD-L1 Inhibitors,” Molecular cancer 17, no. 1 (2018): 129.

[194] J. Liu, Z. Chen, Y. Li, W. Zhao, J. Wu, and Z. Zhang, “PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy,” Frontiers in Pharmacology 12 (2021): 731798.

[195] Y. Liu, J. He, M. Li, K. Ren, and Z. Zhao, “Inflammation-Driven Nanohitchhiker Enhances Postoperative Immunotherapy by Alleviating Prostaglandin E2-Mediated Immunosuppression,” ACS Applied Materials & Interfaces 16, no. 6 (2024): 6879–6893.

[196] K. L. Wang, C. H. Li, P. X. Huang, et al., “Reprogrammed Lung Metastasis Immunodeficiency via Targeted Penetrated Delivery of M1 Macrophage-Wrapped NanoCubes-Mediated T Cell Infiltration,” Small 21, no. 3 (2025): e2406790.

[197] Z. Li, X. Zhang, C. Liu, et al., “Engineering a Nano-Drug Delivery System to Regulate m6A Modification and Enhance Immunotherapy in Gastric Cancer,” Acta Biomaterialia 191 (2025): 412–427.

[198] R. Liu, F. Luo, X. Liu, et al., “Biological Response Modifier in Cancer Immunotherapy,” Advances in Experimental Medicine and Biology 909 (2016): 69–138.

[199] X. Cai, Y. H. Chiu, and Z. J. Chen, “The cGAS-cGAMP-STING Pathway of Cytosolic DNA Sensing and Signaling,” Molecular Cell 54, no. 2 (2014): 289–296.

[200] X. Zhang, X. Bai, and Z. J. Chen, “Structures and Mechanisms in the cGAS-STING Innate Immunity Pathway,” Immunity 53, no. 1 (2020): 43–53.

[201] E. Duong, T. B. Fessenden, E. Lutz, et al., “Type I Interferon Activates MHC Class I-Dressed CD11b(+) Conventional Dendritic Cells to Promote Protective Anti-Tumor Cd8(+) T Cell Immunity,” Immunity 55, no. 2 (2022): 308–323.e9.

[202] H. Wang, S. Hu, X. Chen, et al., “cGAS Is Essential for the Antitumor Effect of Immune Checkpoint Blockade,” Proceedings of the National Academy of Sciences 114, no. 7 (2017): 1637–1642.

[203] S. M. Swetter, H. Tsao, C. K. Bichakjian, et al., “Guidelines of Care for the Management of Primary Cutaneous Melanoma,” Journal of the American Academy of Dermatology 80, no. 1 (2019): 208–250.

[204] K. Peris, M. C. Fargnoli, C. Garbe, et al., “Diagnosis and Treatment of Basal Cell Carcinoma: European Consensus–Based Interdisciplinary Guidelines,” European Journal of Cancer 118 (2019): 10–34.

[205] M. P. Schön and M. Schön, “The Small-Molecule Immune Response Modifier Imiquimod – Its Mode of Action and Clinical Use in the Treatment of Skin Cancer,” Expert Opinion on Therapeutic Targets 10, no. 1 (2006): 69–76.

[206] Y. Deng, F. Jia, P. Jiang, et al., “Biomimetic Nanoparticle Synchronizing Pyroptosis Induction and Mitophagy Inhibition for Anti-Tumor Therapy,” Biomaterials 301 (2023): 122293.

[207] Y. Wang, W. Gao, X. Shi, et al., “Chemotherapy Drugs Induce Pyroptosis Through Caspase-3 Cleavage of a Gasdermin,” Nature 547, no. 7661 (2017): 99–103.

[208] W. Zhen, Y. Liu, S. An, et al., “Glutathione-Induced In Situ Michael Addition Between Nanoparticles for Pyroptosis and Immunotherapy,” Angewandte Chemie-International Edition in English 62, no. 20 (2023): e202301866.

[209] F. Ding, J. Liu, K. Ai, et al., “Simultaneous Activation of Pyroptosis and cGAS-STING Pathway With Epigenetic/Photodynamic Nanotheranostic for Enhanced Tumor Photoimmunotherapy,” Advanced Materials 36, no. 7 (2024): e2306419.

[210] Y. Chao, C. Liang, H. Tao, et al., “Localized Cocktail Chemoimmunotherapy After In Situ Gelation to Trigger Robust Systemic Antitumor Immune Responses,” Science Advances 6, no. 10 (2020): eaaz4204.

[211] E. A. Scott, A. Stano, M. Gillard, A. C. Maio-Liu, M. A. Swartz, and J. A. Hubbell, “Dendritic Cell Activation and T Cell Priming With Adjuvant- and Antigen-Loaded Oxidation-Sensitive Polymersomes,” Biomaterials 33, no. 26 (2012): 6211–6219.

[212] Q. Chen, L. Xu, C. Liang, C. Wang, R. Peng, and Z. Liu, “Photothermal Therapy With Immune-Adjuvant Nanoparticles Together With Checkpoint Blockade for Effective Cancer Immunotherapy,” Nature Communications 7 (2016): 13193.

[213] A. M. Krieg, “Therapeutic Potential of Toll-Like Receptor 9 Activation,” Nature Reviews Drug Discovery 5, no. 6 (2006): 471–484.

[214] C. Braumann, M. Schoenbeck, C. Menenakos, M. Kilian, and C. A. Jacobi, “Effects of Increasing Doses of a Bolus Injection and an Intravenous Long-Term Therapy of Taurolidine on Subcutaneous (Metastatic) Tumor Growth in Rats,” Clinical & Experimental Metastasis 22, no. 1 (2005): 77–83.

[215] R. A. Sheth, R. Murthy, D. S. Hong, et al., “Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer,” JAMA Network Open 3, no. 7 (2020): e207911.

[216] S. Huang, T. Wen, J. Wang, et al., “Nanoparticle-Integrated Dissolving Microneedles for the Co-Delivery of R848/aPD-1 to Synergistically Reverse the Immunosuppressive Microenvironment of Triple-Negative Breast Cancer,” Acta Biomaterialia 176 (2024): 344–355.

[217] Y. Moon, H. Cho, J. Kim, et al., “Self-Assembled Peptide-Derived Proteolysis-Targeting Chimera (PROTAC) Nanoparticles for Tumor-Targeted and Durable PD-L1 Degradation in Cancer Immunotherapy,” Angewandte Chemie-international Edition in English 64, no. 5 (2025): e202414146.

[218] E. Aytekin, S. Maksoud, B. A. Tannous, S. B. Pehlivan, and C. E. Badr, “Dual-Action Nanotherapy: Temozolomide-Loaded, Anti-PD-L1 ScFv-Functionalized Lipid Nanocarriers for Targeted Glioblastoma Therapy,” European Journal of Pharmaceutical Sciences 213 (2025): 107255.

[219] J. T. Crowl, E. E. Gray, K. Pestal, H. E. Volkman, and D. B. Stetson, “Intracellular Nucleic Acid Detection in Autoimmunity,” Annual Review of Immunology 35 (2017): 313–336.

[220] K. W. Chung, P. Dhillon, S. Huang, et al., “Mitochondrial Damage and Activation of the STING Pathway Lead to Renal Inflammation and Fibrosis,” Cell Metabolism 30, no. 4 (2019): 784–799.e5.

[221] A. Bhardwaj, J. Kaur, M. Wuest, and F. Wuest, “In Situ Click Chemistry Generation of Cyclooxygenase-2 Inhibitors,” Nature Communications 8, no. 1 (2017): 1.

[222] Y. Liu, Y. Cai, L. Liu, Y. Wu, and X. Xiong, “Crucial Biological Functions of CCL7 in Cancer,” PeerJ 6 (2018): e4928.

[223] T. M. Nywening, B. A. Belt, D. R. Cullinan, et al., “Targeting Both Tumour-Associated CXCR2(+) Neutrophils and CCR2(+) Macrophages Disrupts Myeloid Recruitment and Improves Chemotherapeutic Responses in Pancreatic Ductal Adenocarcinoma,” Gut 67, no. 6 (2018): 1112–1123.

[224] M. Noel, E. M. O'reilly, B. M. Wolpin, et al., “Phase 1b Study of a Small Molecule Antagonist of Human Chemokine (C-C Motif) Receptor 2 (PF-04136309) in Combination With nab-Paclitaxel/Gemcitabine in First-Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma,” Investigational New Drugs 38, no. 3 (2020): 800–811.

[225] Z. Wan, H. Huang, R. E. West, 3rd, et al., “Overcoming Pancreatic Cancer Immune Resistance by Codelivery of CCR2 Antagonist Using a STING-Activating Gemcitabine-Based Nanocarrier,” Materials Today 62 (2023): 33–50.

[226] M. Lv, M. Chen, R. Zhang, et al., “Manganese Is Critical for Antitumor Immune Responses via cGAS-STING and Improves the Efficacy of Clinical Immunotherapy,” Cell Research 30, no. 11 (2020): 966–979.

[227] C. Wang, Y. Guan, M. Lv, et al., “Manganese Increases the Sensitivity of the cGAS-STING Pathway for Double-Stranded DNA and Is Required for the Host Defense Against DNA Viruses,” Immunity 48, no. 4 (2018): 675–687.e7.

[228] S. Zhou, T. Su, F. Cheng, et al., “Engineering cGAS-Agonistic Oligonucleotides as Therapeutics for Cancer Immunotherapy,” Molecular Therapy. Nucleic Acids 35, no. 1 (2024): 102126.

[229] Z. L. Gao, W. Xu, S. J. Zheng, Q. J. Duan, R. Liu, and J. Z. Du, “Orchestrated Cytosolic Delivery of Antigen and Adjuvant by Manganese Ion-Coordinated Nanovaccine for Enhanced Cancer Immunotherapy,” Nano Letters 23, no. 5 (2023): 1904–1913.

[230] P. Sharma and J. P. Allison, “Immune Checkpoint Therapy: Forging Ahead,” Science Translational Medicine 14, no. 670 (2022): eadf2947.

[231] D. Fukumura, J. Kloepper, Z. Amoozgar, D. G. Duda, and R. K. Jain, “Enhancing Cancer Immunotherapy Using Antiangiogenics: Opportunities and Challenges,” Nature Reviews Clinical Oncology 15, no. 5 (2018): 325–340.

[232] A. Tanaka and S. Sakaguchi, “Targeting Treg Cells in Cancer Immunotherapy,” European Journal of Immunology 49, no. 8 (2019): 1140–1146.

[233] A. Tanaka and S. Sakaguchi, “Regulatory T Cells in Cancer Immunotherapy,” Cell Research 27, no. 1 (2017): 109–118.

[234] L. Li, X. Liu, K. L. Sanders, et al., “TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy,” Cell Metabolism 29, no. 1 (2019): 103–123.e5.

[235] C. Zhao, X. Pang, Z. Yang, S. Wang, H. Deng, and X. Chen, “Nanomaterials Targeting Tumor Associated Macrophages for Cancer Immunotherapy,” Journal of Controlled Release 341 (2022): 272–284.

[236] Z. Duan and Y. Luo, “Targeting Macrophages in Cancer Immunotherapy,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 127.

[237] A. Mantovani, P. Allavena, F. Marchesi, and C. Garlanda, “Macrophages as Tools and Targets in Cancer Therapy,” Nature Reviews Drug Discovery 21, no. 11 (2022): 799–820.

[238] R. A. Sierra, J. Trillo-Tinoco, E. Mohamed, et al., “Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance,” Cancer Research 77, no. 20 (2017): 5628–5638.

[239] Y. Liu, G. Wei, W. A. Cheng, et al., “Targeting Myeloid-Derived Suppressor Cells for Cancer Immunotherapy,” Cancer Immunology, Immunotherapy 67, no. 8 (2018): 1181–1195.

[240] D. C. Hinshaw and L. A. Shevde, “The Tumor Microenvironment Innately Modulates Cancer Progression,” Cancer Research 79, no. 18 (2019): 4557–4566.

[241] K. White, K. Connor, M. Meylan, et al., “Identification, Validation and Biological Characterisation of Novel Glioblastoma Tumour Microenvironment Subtypes: Implications for Precision Immunotherapy,” Annals of Oncology 34, no. 3 (2023): 300–314.

[242] J. Y. F. Chung, P. C. T. Tang, M. K. K. Chan, et al., “Smad3 Is Essential for Polarization of Tumor-Associated Neutrophils in Non-Small Cell Lung Carcinoma,” Nature Communications 14, no. 1 (2023): 1794.

[243] Z. G. Fridlender, J. Sun, S. Kim, et al., “Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” Versus “N2” TAN,” Cancer Cell 16, no. 3 (2009): 183–194.

[244] H. Li, J. Zeng, Q. You, et al., “X-Ray-Activated Nanoscintillators Integrated With Tumor-Associated Neutrophils Polarization for Improved Radiotherapy in Metastatic Colorectal Cancer,” Biomaterials 316 (2025): 123031.

[245] B. Wang, J. Zhou, R. Li, et al., “Activating CD8(+) T Cells by Pt(IV) Prodrug-Based Nanomedicine and aPD-L1 Antibody for Enhanced Cancer Immunotherapy,” Advanced Materials 36, no. 21 (2024): e2311640.

[246] I. X. Chen, V. P. Chauhan, J. Posada, et al., “Blocking CXCR4 Alleviates Desmoplasia, Increases T-Lymphocyte Infiltration, and Improves Immunotherapy in Metastatic Breast Cancer,” Proceedings of the National Academy of Sciences 116, no. 10 (2019): 4558–4566.

[247] R. Mezzapelle, M. Leo, F. Caprioglio, et al., “CXCR4/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy,” Cancers 14, no. 9 (2022): 2314.

[248] M. Groblewska, A. Litman-Zawadzka, and B. Mroczko, “The Role of Selected Chemokines and Their Receptors in the Development of Gliomas,” International Journal of Molecular Sciences 21, no. 10 (2020): 3704.

[249] M. S. Alghamri, K. Banerjee, A. A. Mujeeb, et al., “Systemic Delivery of an Adjuvant CXCR4–CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy,” ACS Nano 16, no. 6 (2022): 8729–8750.

[250] Z. Li, Y. Wang, Y. Shen, C. Qian, D. Oupicky, and M. Sun, “Targeting Pulmonary Tumor Microenvironment With CXCR4-Inhibiting Nanocomplex to Enhance anti–PD-L1 Immunotherapy,” Science Advances 6, no. 20 (2020): eaaz9240.

[251] R. Wei, J. Li, W. Lin, et al., “Nanoparticle-Mediated Blockade of CXCL12/CXCR4 Signaling Enhances Glioblastoma Immunotherapy: Monitoring Early Responses With MRI Radiomics,” Acta Biomaterialia (2024).

[252] D. B. Doroshow, S. Bhalla, M. B. Beasley, et al., “PD-L1 as a Biomarker of Response to Immune-Checkpoint Inhibitors,” Nature Reviews Clinical Oncology 18, no. 6 (2021): 345–362.

[253] C. Tibaldi, A. Lunghi, and E. Baldini, “Use of Programmed Cell Death Protein Ligand 1 Assay to Predict the Outcomes of Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors,” World Journal of Clinical Oncology 8, no. 4 (2017): 320–328.

[254] C. Sun, R. Mezzadra, and T. N. Schumacher, “Regulation and Function of the PD-L1 Checkpoint,” Immunity 48, no. 3 (2018): 434–452.

[255] S. Chen, G. A. Crabill, T. S. Pritchard, et al., “Mechanisms Regulating PD-L1 Expression on Tumor and Immune Cells,” Journal for Immunotherapy of Cancer 7, no. 1 (2019): 305.

[256] Y. J. Lim, J. Koh, S. Kim, et al., “Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8(+) Tumor-Infiltrating Lymphocytes Identified Patients With Poor Prognosis in Rectal Cancer: A Matched Comparison Analysis,” International Journal of Radiation Oncology Biology Physics 99, no. 5 (2017): 1216–1224.

[257] W. L. Liu, Y. Q. Zhang, L. T. Li, et al., “Application of Molecular Imaging in Immune Checkpoints Therapy: From Response Assessment to Prognosis Prediction,” Critical Reviews in Oncology/Hematology 176 (2022): 103746.

[258] R. L. Maute, S. R. Gordon, A. T. Mayer, et al., “Engineering High-Affinity PD-1 Variants for Optimized Immunotherapy and Immuno-PET Imaging,” Proceedings of the National Academy of Sciences 112, no. 47 (2015): E6506–E6514.

[259] S. Heskamp, W. Hobo, J. D. M. Molkenboer-Kuenen, et al., “Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti–PD-L1 Antibodies,” Cancer Research 75, no. 14 (2015): 2928–2936.

[260] A. Josefsson, J. R. Nedrow, S. Park, et al., “Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer,” Cancer Research 76, no. 2 (2016): 472–479.

[261] W. G. Lesniak, S. Chatterjee, M. Gabrielson, et al., “PD-L1 Detection in Tumors Using [64Cu] Atezolizumab With PET,” Bioconjugate Chemistry 27, no. 9 (2016): 2103–2110.

[262] Y. Su, B. Yu, S. Wang, H. Cong, and Y. Shen, “NIR-II Bioimaging of Small Organic Molecule,” Biomaterials 271 (2021): 120717.

[263] Z. Hu, C. Fang, B. Li, et al., “First-in-Human Liver-Tumour Surgery Guided by Multispectral Fluorescence Imaging in the Visible and Near-Infrared-I/II Windows,” Nature Biomedical Engineering 4, no. 3 (2020): 259–271.

[264] W. L. Liu, Y. Q. Zhang, X. J. Luo, et al., “Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer,” International Journal of Nanomedicine 18 (2023): 5141–5157.

[265] Y. Du, X. Liang, Y. Li, et al., “Liposomal Nanohybrid Cerasomes Targeted to PD-L1 Enable Dual-Modality Imaging and Improve Antitumor Treatments,” Cancer Letters 414 (2018): 230–238.

[266] M. Wei, X. Shen, X. Fan, J. Li, and J. Bai, “PD-L1 Aptamer-Functionalized Degradable Hafnium Oxide Nanoparticles for Near Infrared—II Diagnostic Imaging and Radiosensitization,” Frontiers in Bioengineering and Biotechnology 11 (2023): 1224339.

[267] B. Choi, H. Choi, B. Yu, and D. H. Kim, “Synergistic Local Combination of Radiation and Anti-Programmed Death Ligand 1 Immunotherapy Using Radiation-Responsive Splintery Metallic Nanocarriers,” ACS Nano 14, no. 10 (2020): 13115–13126.

[268] Y. Zhang, R. N. Sriramaneni, P. A. Clark, et al., “Multifunctional Nanoparticle Potentiates the In Situ Vaccination Effect of Radiation Therapy and Enhances Response to Immune Checkpoint Blockade,” Nature Communications 13, no. 1 (2022): 4948.

[269] Y. Zhang, M. M. Rahman, P. A. Clark, et al., “In Situ Vaccination Following Intratumoral Injection of IL2 and Poly-L-Lysine/Iron Oxide/CpG Nanoparticles to a Radiated Tumor Site,” ACS Nano 17, no. 11 (2023): 10236–10251.

[270] Y. Hu, S. Paris, H. Barsoumian, et al., “Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects,” International Journal of Radiation Oncology Biology Physics 111, no. 3 (2021): 647–657.

[271] Y. Chao, L. Xu, C. Liang, et al., “Combined Local Immunostimulatory Radioisotope Therapy and Systemic Immune Checkpoint Blockade Imparts Potent Antitumour Responses,” Nature Biomedical Engineering 2, no. 8 (2018): 611–621.

[272] Q. Chen, L. Feng, J. Liu, et al., “Intelligent Albumin–MnO₂ Nanoparticles as pH-/H₂O₂-Responsive Dissociable Nanocarriers to Modulate Tumor Hypoxia for Effective Combination Therapy,” Advanced Materials 28, no. 33 (2016): 7129–7136.

[273] X. Guan, L. Sun, Y. Shen, et al., “Nanoparticle-Enhanced Radiotherapy Synergizes With PD-L1 Blockade to Limit Post-Surgical Cancer Recurrence and Metastasis,” Nature Communications 13, no. 1 (2022): 2834.

[274] N. Zaffaroni and G. L. Beretta, “Nanoparticles for Ferroptosis Therapy in Cancer,” Pharmaceutics 13 (2021): 1785.

[275] H. Song, H. Sun, N. He, et al., “Glutathione Depletion-Induced Versatile Nanomedicine for Potentiating the Ferroptosis to Overcome Solid Tumor Radioresistance and Enhance Immunotherapy,” Adv Healthc Mater 13, no. 9 (2024): e2303412.

[276] S. Du, C. Chen, S. Qu, et al., “DNAzyme-Assisted Nano-Herb Delivery System for Multiple Tumor Immune Activation,” Small 18, no. 45 (2022): e2203942.

[277] Q. Lu, R. Chen, S. Du, et al., “Activation of the cGAS-STING Pathway Combined With CRISPR-Cas9 Gene Editing Triggering Long-Term Immunotherapy,” Biomaterials 291 (2022): 121871.

[278] J. Yang, C. Zhang, X. Chen, et al., “Ultra-Efficient Radio-Immunotherapy for Reprogramming the Hypoxic and Immunosuppressive Tumor Microenvironment With Durable Innate Immune Memory,” Biomaterials 302 (2023): 122303.

[279] J. Wu, Y. Xu, Y. Zhang, et al., “Genetically Engineered Magnesium/Manganese Nanoparticles for Cancer Radioimmunotherapy,” Journal of Nanobiotechnology 23, no. 1 (2025): 593.

[280] M. Kaparakis-Liaskos and R. L. Ferrero, “Immune Modulation by Bacterial Outer Membrane Vesicles,” Nature Reviews Immunology 15, no. 6 (2015): 375–387.

[281] L. Hang, "Bacterial-Based Nanoenzymes With Immune-activating Properties for Enhanced Radioimmunotherapy," MA thesis, Anhui Polytechnic University (2023).

[282] P. Pan, X. Dong, Y. Chen, J. J. Ye, Y. X. Sun, and X. Z. Zhang, “A Heterogenic Membrane-Based Biomimetic Hybrid Nanoplatform for Combining Radiotherapy and Immunotherapy Against Breast Cancer,” Biomaterials 289 (2022): 121810.

[283] Y. Meng, Q. Ba, J. Yao, et al., “Targeted Reprogramming of Tumor Cells by Digoxin-Loaded Immunogenic Nanoparticles Enhances Immunity Against Disseminated Tumor Cells,” Advanced Healthcare Materials 15, no.1 (2025): e02881.

[284] M. S. Chi, D. C. Tien, and K. H. Chi, “Inhomogeneously Distributed Ferroptosis With a High Peak-to-Valley Ratio May Improve the Antitumor Immune Response,” Frontiers in Oncology 13 (2023): 1178681.

[285] Y. Hu, S. Paris, N. Sahoo, et al., “Nanoparticle-Enhanced Proton Beam Immunoradiotherapy Drives Immune Activation and Durable Tumor Rejection,” JCI Insight 8, no. 12 (2023): e167749.

[286] M. Zhang, W. Wang, M. Mohammadniaei, et al., “Upregulating Aggregation-Induced-Emission Nanoparticles With Blood-Tumor-Barrier Permeability for Precise Photothermal Eradication of Brain Tumors and Induction of Local Immune Responses,” Advanced Materials 33, no. 22 (2021): e2008802.

[287] X. Liu, Q. Niu, H. Yang, et al., “Outer Membrane Vesicles-Based Nano-Regulator for Cancer Immunotherapy by Modulating Neutrophils N1 Polarization and Hitchhiking Delivery,” Journal of Nanobiotechnology 23, no. 1 (2025): 638.

[288] Q. Chen, G. Huang, W. Wu, et al., “A Hybrid Eukaryotic-Prokaryotic Nanoplatform With Photothermal Modality for Enhanced Antitumor Vaccination,” Advanced Materials 32, no. 16 (2020): e1908185.

[289] X. Qian, Y. Zheng, and Y. Chen, “Micro/Nanoparticle-Augmented Sonodynamic Therapy (SDT): Breaking the Depth Shallow of Photoactivation,” Advanced Materials 28, no. 37 (2016): 8097–8129.

[290] W. A. Schmidt, “Vascular Ultrasound in Rheumatology Practice,” Best Practice & Research Clinical Rheumatology 37, no. 1 (2023): 101847.

[291] S. Mureşan, M. O. Mărginean, S. Voidăzan, I. Vlasa, and I. Sîntean, “Musculoskeletal Ultrasound: A Useful Tool for Diagnosis of Hip Developmental Dysplasia: One Single-Center Experience,” Medicine 98, no. 2 (2019): e14081.

[292] W. Yue, L. Chen, L. Yu, et al., “Checkpoint Blockade and Nanosonosensitizer-Augmented Noninvasive Sonodynamic Therapy Combination Reduces Tumour Growth and Metastases in Mice,” Nature Communications 10, no. 1 (2019): 2025.

[293] D. Wang, L. Lin, T. Li, et al., “Etching Bulk Covalent Organic Frameworks into Nanoparticles of Uniform and Controllable Size by the Molecular Exchange Etching Method for Sonodynamic and Immune Combination Antitumor Therapy,” Advanced Materials 34, no. 45 (2022): e2205924.

[294] H. Jiao, Q. Mao, N. Razzaq, R. Ankri, and J. Cui, “Ultrasound Technology Assisted Colloidal Nanocrystal Synthesis and Biomedical Applications,” Ultrasonics Sonochemistry 103 (2024): 106798.

[295] M. Payne, S. H. Bossmann, and M. T. Basel, “Direct Treatment Versus Indirect: Thermo-Ablative and Mild Hyperthermia Effects[J],” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 12, no. 5 (2020): e1638.

[296] M. Zhang, W. Wang, F. Wu, et al., “Biodegradable Poly (γ-glutamic Acid)@Glucose Oxidase@Carbon Dot Nanoparticles for Simultaneous Multimodal Imaging and Synergetic Cancer Therapy,” Biomaterials 252 (2020): 120106.

[297] W. Sun, Y. Du, X. Liang, et al., “Synergistic Triple-Combination Therapy With Hyaluronic Acid-Shelled PPy/CPT Nanoparticles Results in Tumor Regression and Prevents Tumor Recurrence and Metastasis in 4T1 Breast Cancer,” Biomaterials 217 (2019): 119264.

[298] C. Boutros, A. Tarhini, E. Routier, et al., “Safety Profiles of anti-CTLA-4 and anti-PD-1 Antibodies Alone and in Combination,” Nature Reviews Clinical Oncology 13, no. 8 (2016): 473–486.

[299] Q. Yu, X. Tang, W. Zhao, et al., “Mild Hyperthermia Promotes Immune Checkpoint Blockade-Based Immunotherapy Against Metastatic Pancreatic Cancer Using Size-Adjustable Nanoparticles,” Acta Biomaterialia 133 (2021): 244–256.

[300] C. Le Tourneau, X. Liem, F. Nguyen, et al., “Intratumoral Radioenhancer Nanoparticle NBTXR3 Followed by Radiotherapy in Head and Neck Cancer: A Phase 1 Dose-Expansion Nonrandomized Clinical Trial,” JAMA Otolaryngology–Head & Neck Surgery 152, no. 3 (2026): 284–293.

[301] S. Bonvalot, P. L. Rutkowski, J. Thariat, et al., “NBTXR3, a First-In-Class Radioenhancer Hafnium Oxide Nanoparticle, Plus Radiotherapy Versus Radiotherapy Alone in Patients With Locally Advanced Soft-Tissue Sarcoma (Act.In.Sarc): A Multicentre, Phase 2–3, Randomised, Controlled Trial,” Lancet Oncology 20, no. 8 (2019): 1148–1159.

[302] C. Verry, S. Dufort, J. Villa, et al., “Theranostic AGuIX Nanoparticles as Radiosensitizer: A Phase I, Dose-Escalation Study in Patients With Multiple Brain Metastases (NANO-RAD Trial),” Radiotherapy and Oncology 160 (2021): 159–165.

[303] C. Chargari, P. Maury, M. Texier, et al., “Theragnostic Gadolinium-Based Nanoparticles Safely Augment X-Ray Radiation Effects in Patients With Cervical Cancer,” ACS Nano 18, no. 26 (2024): 16516–16529.

[304] R. J. Sullivan, O. O. Yeku, D. Teoh, et al., “First-In-Human Phase I/II, Open-Label Study of mRNA-2416 Alone or Combined With Durvalumab in Patients With Advanced Solid Tumors and Ovarian Cancer[J],” Oncologist 30, no. 6 (2025): oyaf115.

[305] M. M. Milhem, T. M. Wise-Draper, S. Chandra, et al., “Phase 1b/2 Study Evaluating Safety, Efficacy and Immune Effects of TLR9 Agonist Cavrotolimod With Anti-PD-1 Antibodies Among Patients With Advanced Solid Tumors,” Journal for Immunotherapy of Cancer 13, no. 7 (2025): e011651.

[306] P. H. Thaker, D. L. Richardson, A. R. Hagemann, et al., “OVATION-2: A Randomized Phase I/II Study Evaluating the Safety and Efficacy of IMNN-001 (IL-12 Gene Therapy) With Neo/Adjuvant Chemotherapy in Patients Newly-Diagnosed With Advanced Epithelial Ovarian Cancer,” Gynecologic Oncology 197 (2025): 182–191.

Rights & permissions

2026 The Author(s). MedComm – Biomaterials and Applications published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).